NCT07731958

Brief Summary

This study compares two surgical approaches for patients with severe Chronic Obstructive Pulmonary Disease (COPD) and severe emphysema: unilateral (operating on one lung) versus bilateral (operating on both lungs) lung volume reduction surgery (LVRS).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
146

participants targeted

Target at P75+ for not_applicable

Timeline
72mo left

Started Mar 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress19%
Mar 2025Jul 2032

Study Start

First participant enrolled

March 21, 2025

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

July 17, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 28, 2026

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2031

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2032

Last Updated

July 28, 2026

Status Verified

July 1, 2026

Enrollment Period

6.3 years

First QC Date

July 17, 2026

Last Update Submit

July 22, 2026

Conditions

Keywords

Thoracic surgeryVATSLVRSLung volume reduction surgeryLung functionMortalityDyspnea

Outcome Measures

Primary Outcomes (1)

  • Lung function

    Change in Forced Expiratory Volume in 1 second, or FEV1) is the primary outcome. All parameters in a complete lunge function test will be evaluated including diffusion capacity of the lung for carbon monoxide, residual volume, total lung capacity, RV-to-TLC ratio.

    3 months and 12 months after surgery

Secondary Outcomes (1)

  • Mortality

    Thirty days from surgery

Other Outcomes (9)

  • Dyspnea

    3 and 12 months after surgery

  • Physical activity

    3 and 12 months after surgery

  • Postoperative complications

    During admission

  • +6 more other outcomes

Study Arms (2)

Bilateral LVRS

EXPERIMENTAL
Procedure: Bilateral LVRS

Unilateral LVRS

ACTIVE COMPARATOR
Procedure: Unilateral LVRS

Interventions

Both unilateral and bilateral LVRS are done with a standardized 3 port VATS access. Lower ligament is freed, no graspers on the parenchyma and stapling of the selected areas with a Signia™ powered stapler with Tri-Staple™ technology (Medtronic). The reloads will not be butressed and it will be vascular or parenchymal reloads. Two drains will be placed on the operated side and the same pain management will be applied including perioperative blocs and a pain catheter. The unilateral procedures will be performed with the patient in a side position. Postoperatively the drains will be removed when there is no sign of air leakage on the digital chest drain system. Chest x-ray will be performed to secure a fully inflated lung before discharge.

Unilateral LVRS

Both unilateral and bilateral LVRS are done with a standardized 3 port VATS access. Lower ligament is freed, no graspers on the parenchyma and stapling of the selected areas with a Signia™ powered stapler with Tri-Staple™ technology (Medtronic). The reloads will not be butressed and it will be vascular or parenchymal reloads. Two drains will be placed on the operated side and the same pain management will be applied including perioperative blocs and a pain catheter. In the bilateral procedures the paBent will be positioned on the back and the side to be operated on liked by rotating the table. The surgeon is free to decide which side to deal with first. Postoperatively the drains will be removed when there is no sign of air leakage on the digital chest drain system. Chest x-ray will be performed to secure a fully inflated lung before discharge.

Bilateral LVRS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Suitable target areas in both lungs
  • Age ≥ 18 years.
  • Speaks and understands Danish or English
  • Informed consent obtained
  • Moderate to severe COPD with MRC score \> 2 \< 75 years old 17 \< BMI \> 30 FEV1 \> 20% and \< 45% of predicted RV \> 200% of predicted as a sign of relevant hyperinflation DLCO \> 20% of predicted The patient should be in ideal medical treatment and have completed rehabilitation A high-resolution CT \< 3 months old should follow the referral to MDT Absence of nodules suspicious of malignancy on CT scan Absence of significant comorbidity including severe cardiovascular disease LVEF normal Absence of pulmonary hypertension, TI-gradient \< 40 mmHg Absence of chronic or frequent lung infections Smoking abstinence six months prior to surgery Assessed as sufficiently physically fit to undergo surgery and rehabilitation

You may not qualify if:

  • Dependent on wheelchair
  • Living in nursery home
  • Dependent on walker device
  • Psychiatric disorder (anxiety, depression, schizophrenia)
  • Simultaneous lung cancer surgery
  • Massive adhesions during surgery assessed by the surgeon indicating problems postoperatively
  • Increased risk of post-operative bleeding assessed perioperatively by the surgeon.
  • Perioperative decision on not doing operation on the other side (medical, surgical or anaesthesiologic problems that favours a fast termination of the surgery, decided by the team in OR).
  • Previous cardiothoracic surgery
  • Increased bleeding risk (e.g., preoperative INR \>2, overdue discontinuation of anticoagulants according to guidelines by the Danish Society for Thrombosis and Haemostasis, known coagulopathy).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rigshospitalet

Copenhagen, 2300, Denmark

RECRUITING

MeSH Terms

Conditions

Pulmonary EmphysemaDyspnea

Condition Hierarchy (Ancestors)

Pulmonary Disease, Chronic ObstructiveLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsRespiration DisordersSigns and Symptoms, RespiratorySigns and Symptoms

Central Study Contacts

Alberte Lund, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Type of Study: Single-center, open-label, 1:1 randomized controlled trial. Sample Size: The study aims to enroll 146 patients in total, with 73 patients randomly assigned to each group. Key Inclusion Criteria: Patients under 75 years old with moderate-to-severe COPD, suitable surgical targets in both lungs, severe lung hyperinflation, and at least six months of smoking abstinence. Key Exclusion Criteria: Dependence on a wheelchair or walker, living in a nursing home, active psychiatric disorders, or a history of previous cardiothoracic surgery.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD and Phd student

Study Record Dates

First Submitted

July 17, 2026

First Posted

July 28, 2026

Study Start

March 21, 2025

Primary Completion (Estimated)

July 1, 2031

Study Completion (Estimated)

July 1, 2032

Last Updated

July 28, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations